Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2011

View Archived Issues

Novel pyridin-2-ylmethylamine derivatives inhibit beta-amyloid aggregation in vitro

Shionogi & Co. presents new endothelial lipase inhibitors

Scientists at Bristol-Myers Squibb synthesize new HCV NS5A inhibitors

New aminopyrimidine gamma-secretase modulators show promise as AD therapeutics in vivo

Novel inhibitors of tyrosine-protein kinase SYK patented

Activity in models of AD observed with new small-molecule beta-amyloid toxicity inhibitor

Meiji Seika discloses new triterpene derivatives for HCV infection

Phase I tolerability data presented on CHF-5074

New estrogen-related receptor-alpha inverse agonists reported

Graceway Pharmaceuticals gains FDA approval for Zyclara cream

Seek completes proof-of-efficacy phase Ib/II trial of HIV-v vaccine

Phase II study begins for CNV-1014802 in pain

Roche to acquire mtm laboratories

Pfizer withdraws application to extend Macugen indication in E.U.

Novartis launches Exelon patch in Japan

Janssen launches Tramcet combination tablet in Japan

FDA clears Luminex's xTAG RVP FAST frontline respiratory panel

BrainStorm Cell Therapeutics and U.S. medical centers prepare for ALS trial collaboration

FDA committee issues opinion on approval of dapagliflozin for type 2 diabetes

Allergan enters definitive agreement to acquire Vicept Therapeutics

Alkermes provides update on merger and product portfolio

Galapagos small-molecule SARM enters proof-of-mechanism phase I trial

Cel-Sci and Teva Pharmaceutical extend Multikine licensing agreement

Shionogi to acquire nine marketed products from Victory Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...